Savara (NASDAQ:SVRA) Trading Down 3.5%

Savara Inc (NASDAQ:SVRA) shares dropped 3.5% on Tuesday . The company traded as low as $4.38 and last traded at $4.45. Approximately 175,809 shares changed hands during trading, a decline of 85% from the average daily volume of 1,211,821 shares. The stock had previously closed at $4.61.

Analyst Ratings Changes

SVRA has been the subject of several analyst reports. Guggenheim raised their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Savara in a report on Wednesday, August 14th. Finally, Oppenheimer lifted their price target on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Savara has an average rating of “Buy” and a consensus price target of $11.17.

Savara Trading Down 6.5 %

The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The company has a market cap of $595.59 million, a P/E ratio of -12.24 and a beta of 0.97. The business has a 50-day moving average price of $4.38 and a two-hundred day moving average price of $4.48.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, analysts predict that Savara Inc will post -0.44 EPS for the current year.

Hedge Funds Weigh In On Savara

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Savara in the 2nd quarter valued at approximately $215,000. Nantahala Capital Management LLC grew its stake in Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares during the period. Algert Global LLC grew its stake in Savara by 21.0% in the second quarter. Algert Global LLC now owns 238,807 shares of the company’s stock valued at $962,000 after acquiring an additional 41,377 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in shares of Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after acquiring an additional 4,157,385 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC raised its position in shares of Savara by 46.5% during the second quarter. Susquehanna Fundamental Investments LLC now owns 115,831 shares of the company’s stock worth $467,000 after purchasing an additional 36,758 shares during the period. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.